General Thoracic and Cardiovascular Surgery

, Volume 62, Issue 3, pp 191–194 | Cite as

Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity

  • Yoshiki Kozu
  • Mitsuhiro Isaka
  • Yasuhisa Ohde
  • Kengo Takeuchi
  • Takashi Nakajima
Case Report


A 57-year-old Japanese man presented with massive right pleural effusion, and a huge tumor arising in the pleural cavity was detected by chest computed tomography. A thoracoscopic tumor biopsy revealed that the tumor protruded extensively into the pleural cavity, and its gross appearance was cystic and glossy. Microscopically, the tumor cells were rounded and epithelioid in shape. Prominent and abundant myxoid stroma was also present together with an inflammatory infiltrate, and the tumor was anaplastic lymphoma kinase (ALK)-immunopositive. Fluorescence in situ hybridization revealed that the Ran-binding protein 2-ALK fusion gene was present. Taken together, these findings supported the diagnosis of epithelioid inflammatory myofibroblastic sarcoma (EIMS), which is a variant of an inflammatory myofibrobrastic tumor. This is the first reported case of an EIMS arising in the pleural cavity.


Epithelioid inflammatory myofibroblastic sarcoma Inflammatory myofibrobrastic tumor Pleural cavity Ran-binding protein 2—anaplastic lymphoma kinase 


  1. 1.
    Marino-Enriquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, et al. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011;35:135–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Patel AS, Murphy KM, Hawkins AL, Cohen JS, Long PP, Perlman EJ, et al. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet Cytogenet. 2007;176:107–14.PubMedCrossRefGoogle Scholar
  3. 3.
    Chen ST, Lee JC. An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features. Hum Pathol. 2008;39:1854–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M, et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. G Chromoso Cancer. 2003;37:98–105.CrossRefGoogle Scholar
  5. 5.
    Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:1727–33.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Fabre D, Fadel E, Singhal S, de Montpreville V, Mussot S, Mercier O, et al. Complete resection of pulmonary inflammatory pseudotumors has excellent long-term prognosis. J Thorac Cardiovasc Surg. 2009;137:435–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Sakurai H, Hasegawa T, Watanabe S, Suzuki K, Asamura H, Tsuchiya R. Inflammatory myofibroblastic tumor of the lung. Eur J Cardiothorac Surg. 2004;25:155–9.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2013

Authors and Affiliations

  • Yoshiki Kozu
    • 1
  • Mitsuhiro Isaka
    • 1
  • Yasuhisa Ohde
    • 1
  • Kengo Takeuchi
    • 2
  • Takashi Nakajima
    • 3
  1. 1.Division of Thoracic SurgeryShizuoka Cancer CenterNagaizumiJapan
  2. 2.Pathology Project for Molecular Targets, The Cancer InstituteJapanese Foundation for Cancer ResearchTokyoJapan
  3. 3.Division of PathologyShizuoka Cancer CenterShizuokaJapan

Personalised recommendations